|
1
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tran GD, Sun XD, Abnet CC, et al:
Prospective study of risk factors for esophageal and gastric
cancers in the Linxian general population trial cohort in China.
Int J Cancer. 113:456–463. 2005. View Article : Google Scholar
|
|
4
|
Allum WH, Stenning SP, Bancewicz J, et al:
Long-term results of a randomized trial of surgery with or without
preoperative chemotherapy in esophageal cancer. J Clin Oncol.
27:5062–5067. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Song JX, Sze SC, Ng TB, et al:
Anti-Parkinsonian drug discovery from herbal medicines: what have
we got from neurotoxic models? J Ethnopharmacol. 139:698–711. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xie W and Du L: Diabetes is an
inflammatory disease: evidence from traditional Chinese medicines.
Diabetes Obes Metab. 13:289–301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang NB, Huang ZG, Cui WD and Ding BP:
Effects of puerarin on expression of cardiac Smad3 and Smad7 mRNA
in spontaneously hypertensive rat. J Ethnopharmacol. 138:737–740.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mori M, Aizawa T, Tokoro M, et al: Soy
isoflavone tablets reduce osteoporosis risk factors and obesity in
middle-aged Japanese women. Clin Exp Pharmacol Physiol. 31(Suppl
2): S39–S41. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Michihara S, Tanaka T, Uzawa Y, et al:
Puerarin exerted anti-osteoporotic action independent of estrogen
receptor-mediated pathway. J Nutr Sci Vitaminol. 58:202–209. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Benlhabib E, Baker JI, Keyler DE and Singh
AK: Effects of purified puerarin on voluntary alcohol intake and
alcohol withdrawal symptoms in P rats receiving free access to
water and alcohol. J Med Food. 7:180–186. 2004. View Article : Google Scholar
|
|
11
|
Hertog MG, Feskens EJ, Hollman PC, Katan
MB and Kromhout D: Dietary antioxidant flavonoids and risk of
coronary heart disease: the Zutphen Elderly Study. Lancet.
342:1007–1011. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wong KH, Li GQ, Li KM, et al: Kudzu root:
traditional uses and potential medicinal benefits in diabetes and
cardiovascular diseases. J Ethnopharmacol. 134:584–607. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tao HQ, Meng Q, Li MH, et al: HP-β-CD-PLGA
nanoparticles improve the penetration and bioavailability of
puerarin and enhance the therapeutic effects on brain
ischemia-reperfusion injury in rats. Naunyn Schmiedebergs Arch
Pharmacol. 386:61–70. 2013.
|
|
14
|
Yu Z and Li W: Induction of apoptosis by
puerarin in colon cancer HT-29 cells. Cancer Lett. 238:53–60. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Y, Ma Y, Zheng Y, et al: In vitro and
in vivo anticancer activity of a novel puerarin nanosuspension
against colon cancer, with high efficacy and low toxicity. Int J
Pharm. 441:728–735. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li XR, Zhang QQ, Cui YH, et al: The growth
influence on human esophageal cancer cells EC9706 induced by
puerarin. Journal of Oncology Medicine. 2010.1922–1924. 2010.(In
Chinese).
|
|
17
|
Lin YJ, Hou YC, Lin CH, et al: Puerariae
radix isoflavones and their metabolites inhibit growth and induce
apoptosis in breast cancer cells. Biochem Biophys Res Commun.
378:683–688. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hien TT, Kim HG, Han EH, et al: Molecular
mechanism of suppression of MDR1 by puerarin from Pueraria lobata
via NF-kappaB pathway and cAMP-responsive element transcriptional
activity-dependent up-regulation of AMP-activated protein kinase in
breast cancer MCF-7/adr cells. Mol Nutr Food Res. 54:918–928. 2010.
View Article : Google Scholar
|
|
19
|
Yu C, Li Y, Chen H, et al: Decreased
expression of aromatase in the Ishikawa and RL95-2 cells by the
isoflavone, puerarin, is associated with inhibition of c-jun
expression and AP-1 activity. Food Chem Toxicol. 46:3671–3676.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Awad ME, Abdel-Rahman MS and Hassan SA:
Acrylamide toxicity in isolated rat hepatocytes. Toxicol in Vitro.
12:699–704. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen M and Wang J: Initiator caspases in
apoptosis signaling pathways. Apoptosis. 7:313–319. 2002.
View Article : Google Scholar
|
|
22
|
Green DR: Apoptotic pathways: ten minutes
to dead. Cell. 121:671–674. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yeh KH, Yeh SH, Hsu CH, et al: Prolonged
and enhanced suppression of thymidylate synthase by weekly 24-h
infusion of high-dose 5-fluorouracil. Br J Cancer. 83:1510–1515.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu XX, Kakehi Y, Mizutani Y, et al:
Activation of caspase-3 in renal cell carcinoma cells by
anthracyclines or 5-fluorouracil. Int J Oncol. 19:19–24.
2001.PubMed/NCBI
|
|
25
|
Ikebukuro K, Adachi Y, Toki J, et al:
Morphological change, loss of deltapsi(m) and activation of
caspases upon apoptosis of colorectal adenocarcinoma induced by
5-FU. Cancer Lett. 153:101–108. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shears LL, Ribeiro U, Kane J, et al:
apoptosis in esophageal cancer following induction
chemoradiotherapy. J Surg Res. 79:20–24. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Matsuhashi N, Saio M, Matsuo A, et al: The
evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of
induction of apoptosis: time-and p53 expression-dependency of
anti-cancer drugs. Oncol Rep. 14:609–615. 2005.PubMed/NCBI
|
|
28
|
Tian F, Fan T, Zhang Y, et al: Curcumin
potentiates the antitumor effects of 5-FU in treatment of
esophageal squamous carcinoma cells through downregulating the
activation of NF-κB signaling pathway in vitro and in vivo. Acta
Biochim Biophys Sin (Shanghai). 44:847–855. 2012.PubMed/NCBI
|
